BlackRock Amends Kezar Life Sciences Stake as of Dec 31, 2023
Ticker: KZR · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1645666
| Field | Detail |
|---|---|
| Company | Kezar Life Sciences, INC. (KZR) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its Kezar Life Sciences holdings, signaling its latest position in the biotech firm.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership of Kezar Life Sciences, Inc. common stock as of December 31, 2023. This amendment, filed under Rule 13d-1(b), indicates a change in BlackRock's beneficial ownership. For investors, this matters because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in confidence or strategy regarding Kezar Life Sciences, Inc. stock.
Why It Matters
This filing shows BlackRock's updated position in Kezar Life Sciences, Inc., providing transparency on a significant institutional investor's stake, which can influence market perception and trading activity.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of institutional ownership and does not inherently present a direct risk to investors.
Analyst Insight
An investor should note BlackRock's continued or adjusted position in Kezar Life Sciences, Inc. as of December 31, 2023, and consider it as one data point among many when evaluating the stock, without over-interpreting the change in ownership without further context on the specific percentage change.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Kezar Life Sciences, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G/A
- 49372L100 (other) — the CUSIP number for Kezar Life Sciences, Inc. Common Stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a major institutional investment manager.
What is the subject company whose securities are being reported?
The subject company is Kezar Life Sciences, Inc., a pharmaceutical preparations company.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Under which rule was this Schedule 13G/A filed?
This Schedule 13G/A was filed under Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding Kezar Life Sciences, Inc. (KZR).